Inhaled Therapies Will Expand Global Diabetes And Pulmonary Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
07 May 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
US$12.00
65.8% undervalued intrinsic discount20 Aug
US$4.11
1Y
-23.6%7D
7.9%